Skip to main content

HealthTell Completes $26M Series B Financing Round

NEW YORK (GenomeWeb) – Diagnostics developer HealthTell announced today that it has completed a $26 million Series B financing round led by Third Point Ventures.

The company, which also raised $14 million in a previous Series A round, plans to use the proceeds to commercialize panels for tests for autoimmune diseases, such as lupus.

The firm said its Immunosignature Technology platform is best suited to test for these diseases, which can be difficult to diagnose as they mimic other conditions. Instead of directly targeting the disease, the HealthTell test profiles the patient's immune system using a high-density peptide array that is designed to query the antibodies present in a human blood sample, and looks for patterns that correspond to overall health.

HealthTell also said it has developed a pharmaceutical services business that will create companion diagnostics for new and existing drugs. "Our pharmaceutical customers continue to reinforce the need for new tools to stratify patients for drug development trials and to select patients most likely to respond to specific treatments," said CEO Bill Colston in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.